tetano
Editor, Senior Moderator
Drug Saf. 2017 Apr 17. doi: 10.1007/s40264-017-0532-3. [Epub ahead of print]
[h=1]Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt.[/h] Dos Santos G[SUP]1,[/SUP][SUP]2[/SUP], Seifert HA[SUP]3[/SUP], Bauchau V[SUP]4[/SUP], Shinde V[SUP]4,[/SUP][SUP]5[/SUP], Barbeau DM[SUP]6[/SUP], Cohet C[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] We investigated a signal of solid organ transplant (SOT) rejection after immunisation with (AS03) A/H1N1 2009 pandemic influenza vaccines.
[h=4]METHODS:[/h] Potential immunological mechanisms were reviewed and quantitative analyses were conducted. The feasibility of pharmacoepidemiological studies was explored.
[h=4]RESULTS:[/h] Overall results, including data from a pharmacoepidemiological study, support the safety of adjuvanted (AS03) pandemic influenza vaccination in SOT recipients. The regulatory commitment to evaluate the signal through a stepwise investigation was closed in 2014.
[h=4]CONCLUSION:[/h] Lessons learned highlight the importance of investigating plausible biological mechanisms between vaccines and potentially associated adverse outcomes, and the importance of selecting appropriate study settings and designs for safety signal investigations.
PMID: 28417321 DOI: 10.1007/s40264-017-0532-3
[h=1]Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt.[/h] Dos Santos G[SUP]1,[/SUP][SUP]2[/SUP], Seifert HA[SUP]3[/SUP], Bauchau V[SUP]4[/SUP], Shinde V[SUP]4,[/SUP][SUP]5[/SUP], Barbeau DM[SUP]6[/SUP], Cohet C[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]INTRODUCTION:[/h] We investigated a signal of solid organ transplant (SOT) rejection after immunisation with (AS03) A/H1N1 2009 pandemic influenza vaccines.
[h=4]METHODS:[/h] Potential immunological mechanisms were reviewed and quantitative analyses were conducted. The feasibility of pharmacoepidemiological studies was explored.
[h=4]RESULTS:[/h] Overall results, including data from a pharmacoepidemiological study, support the safety of adjuvanted (AS03) pandemic influenza vaccination in SOT recipients. The regulatory commitment to evaluate the signal through a stepwise investigation was closed in 2014.
[h=4]CONCLUSION:[/h] Lessons learned highlight the importance of investigating plausible biological mechanisms between vaccines and potentially associated adverse outcomes, and the importance of selecting appropriate study settings and designs for safety signal investigations.
PMID: 28417321 DOI: 10.1007/s40264-017-0532-3